Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin

Vancomycin is an increasingly important option for the treatment of Clostridium difficile infection, but economic barriers to its use remain significant in the outpatient setting. Generic vancomycin capsules are still inexplicably expensive and not universally covered by insurers. This report highli...

Descripción completa

Detalles Bibliográficos
Autores principales: Bunnell, Kristen L., Danziger, Larry H., Johnson, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472230/
https://www.ncbi.nlm.nih.gov/pubmed/28638841
http://dx.doi.org/10.1093/ofid/ofx078
_version_ 1783244087138189312
author Bunnell, Kristen L.
Danziger, Larry H.
Johnson, Stuart
author_facet Bunnell, Kristen L.
Danziger, Larry H.
Johnson, Stuart
author_sort Bunnell, Kristen L.
collection PubMed
description Vancomycin is an increasingly important option for the treatment of Clostridium difficile infection, but economic barriers to its use remain significant in the outpatient setting. Generic vancomycin capsules are still inexplicably expensive and not universally covered by insurers. This report highlights the potential adverse consequences of cost-related nonadherence to vancomycin therapy and the challenges that clinicians face when prescribing oral vancomycin.
format Online
Article
Text
id pubmed-5472230
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54722302017-06-21 Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin Bunnell, Kristen L. Danziger, Larry H. Johnson, Stuart Open Forum Infect Dis Brief Report Vancomycin is an increasingly important option for the treatment of Clostridium difficile infection, but economic barriers to its use remain significant in the outpatient setting. Generic vancomycin capsules are still inexplicably expensive and not universally covered by insurers. This report highlights the potential adverse consequences of cost-related nonadherence to vancomycin therapy and the challenges that clinicians face when prescribing oral vancomycin. Oxford University Press 2017-04-22 /pmc/articles/PMC5472230/ /pubmed/28638841 http://dx.doi.org/10.1093/ofid/ofx078 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Bunnell, Kristen L.
Danziger, Larry H.
Johnson, Stuart
Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
title Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
title_full Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
title_fullStr Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
title_full_unstemmed Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
title_short Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
title_sort economic barriers in the treatment of clostridium difficile infection with oral vancomycin
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472230/
https://www.ncbi.nlm.nih.gov/pubmed/28638841
http://dx.doi.org/10.1093/ofid/ofx078
work_keys_str_mv AT bunnellkristenl economicbarriersinthetreatmentofclostridiumdifficileinfectionwithoralvancomycin
AT danzigerlarryh economicbarriersinthetreatmentofclostridiumdifficileinfectionwithoralvancomycin
AT johnsonstuart economicbarriersinthetreatmentofclostridiumdifficileinfectionwithoralvancomycin

Ejemplares similares